文献速递肝病消化道肿瘤与早癌

肝硬化患者肝细胞癌风险分层模型

Risk Stratification Model for Hepatocellular Cancer in Patients With Cirrhosis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-04-30

研究利用美国两个前瞻性队列的2431例肝硬化患者开发肝细胞癌风险指数,模型包含年龄、性别、吸烟、饮酒、体质指数、病因、甲胎蛋白、白蛋白、丙氨酸氨基转移酶和血小板等预测因子,C指数为0.77,外部验证队列21550例中2年AUROC为0.70且校准良好,结论认为该指数可区分将发生肝细胞癌的肝硬化患者并有助于指导监测和预防讨论。

要点

  • 模型在2431例肝硬化患者中开发,C指数0.77(95%CI 0.73-0.81),1年AUROC 0.75、2年AUROC 0.77。
  • 外部验证队列21550例中2年AUROC为0.70,校准良好。
  • 预测因子包括年龄、性别、吸烟、饮酒、体质指数、病因、甲胎蛋白、白蛋白、丙氨酸氨基转移酶和血小板。

核心结论

  • 包含客观且常规可获风险因素的风险指数可区分将发生肝细胞癌的肝硬化患者,并有助于指导关于肝细胞癌监测和预防的讨论。
  • 今后需要进一步外部验证和风险分层细化研究。

研究设计与样本

  • 使用美国2个前瞻性队列数据开发风险指数,患者来自8个中心,随访至发生肝细胞癌、死亡或2021年12月31日。
  • 开发队列2431例,平均年龄60岁,女性31%,丙型肝炎治愈24%,酒精性肝病16%,非酒精性脂肪性肝病29%。
  • 采用竞争风险回归重新拟合预测因子,用受试者工作特征曲线下面积(AUROC)评价预测性能。
  • 外部验证队列为2018年至2019年间在美国退伍军人事务部系统就诊的21550例肝硬化患者,随访至2021年。

主要发现

  • 开发队列中模型C指数为0.77(95%CI 0.73-0.81),1年AUROC为0.75(95%CI 0.65-0.85),2年AUROC为0.77(95%CI 0.71-0.83),模型校准良好。
  • 外部验证队列中2年AUROC为0.70,校准 excellent。

关键数值与推荐

  • 预测因子包括年龄、性别、吸烟、饮酒、体质指数、病因、甲胎蛋白、白蛋白、丙氨酸氨基转移酶和血小板水平。
  • 开发队列模型C指数0.77(95%CI 0.73-0.81)。
  • 开发队列1年AUROC 0.75(95%CI 0.65-0.85),2年AUROC 0.77(95%CI 0.71-0.83)。
  • 外部验证队列2年AUROC为0.70。

临床怎么用

  • 原文结论认为该风险指数可区分将发生肝细胞癌的肝硬化患者,并有助于指导关于肝细胞癌监测和预防的讨论。

局限性

  • 原文指出今后需要进一步外部验证和风险分层细化研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The available risk stratification indices for hepatocellular cancer (HCC) have limited applicability. We developed and externally validated an HCC risk stratification index in U.S. cohorts of patients with cirrhosis. METHODS: We used data from 2 prospective U.S. cohorts to develop the risk index. Patients with cirrhosis were enrolled from 8 centers and followed until development of HCC, death, or December 31, 2021. We identified an optimal set of predictors with the highest discriminatory ability (C-index) for HCC. The predictors were refit using competing risk regression and its predictive performance was evaluated using the area under the receiver-operating characteristic curve (AUROC). External validation was performed in a cohort of 21,550 patients with cirrhosis seen in the U.S Veterans Affairs system between 2018 and 2019 with follow-up through 2021. RESULTS: We developed the model in 2431 patients (mean age 60 years, 31% women, 24% cured hepatitis C, 16% alcoholic liver disease, and 29% nonalcoholic fatty liver disease). The selected model had a C-index of 0.77 (95% confidence interval [CI], 0.73-0.81), and the predictors were age, sex, smoking, alcohol use, body mass index, etiology, α-fetoprotein, albumin, alanine aminotransferase, and platelet levels. The AUROCs were 0.75 (95% CI, 0.65-0.85) at 1 year and 0.77 (95% CI, 0.71-0.83) at 2 years, and the model was well calibrated. In the external validation cohort, the AUROC at 2 years was 0.70 with excellent calibration. CONCLUSION: The risk index, including objective and routinely available risk factors, can differentiate patients with cirrhosis who will develop HCC and help guide discussions regarding HCC surveillance and prevention. Future studies are needed for additional external validation and refinement of risk stratification.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Kanwal F, Khaderi S, Singal AG, et al. Risk Stratification Model for Hepatocellular Cancer in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2023. PMID: 37390101. doi:10.1016/j.cgh.2023.04.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。